Cargando…

Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort

BACKGROUND: Tumor mutation burden (TMB) is a biomarker frequently reported by clinical laboratories, which is derived by quantifying of the number of single nucleotide or indel variants (mutations) identified by next-generation sequencing of tumors. TMB values can inform prognosis or predict the res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bevins, Nicholas, Sun, Shulei, Gaieb, Zied, Thorson, John A, Murray, Sarah S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174068/ https://www.ncbi.nlm.nih.gov/pubmed/32217764 http://dx.doi.org/10.1136/jitc-2020-000613

Ejemplares similares

Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity
por: Hong, Tae Hee, et al.
Publicado: (2020)

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
por: Hurkmans, Daan P., et al.
Publicado: (2021)

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
por: Naing, Aung, et al.
Publicado: (2022)

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
por: Rahma, Osama E, et al.
Publicado: (2022)

Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
por: Naidoo, Jarushka, et al.
Publicado: (2021)

Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice
por: Pieper, Alexander A, et al.
Publicado: (2021)

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
por: Papadatos-Pastos, Dionysis, et al.
Publicado: (2022)

Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186
por: Dettling, Danielle E, et al.
Publicado: (2022)

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
por: Shen, Lin, et al.
Publicado: (2020)

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
por: Desai, Jayesh, et al.
Publicado: (2020)

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
por: Luke, Jason J, et al.
Publicado: (2021)

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
por: Taylor, Kirsty, et al.
Publicado: (2020)

Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors
por: Okoye, Isobel, et al.
Publicado: (2020)

Carbohydrate ligand engagement with CD11b enhances differentiation of tumor-associated myeloid cells for immunotherapy of solid cancers
por: Roche, Veronique, et al.
Publicado: (2023)

Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
por: Joerger, Markus, et al.
Publicado: (2023)

Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
por: Razak, Albiruni RA, et al.
Publicado: (2020)

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
por: Hamid, Omid, et al.
Publicado: (2022)

Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
por: Santos, João Manuel, et al.
Publicado: (2020)

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients
por: Machiels, Jean-Pascal, et al.
Publicado: (2020)

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
por: Sanborn, Rachel E, et al.
Publicado: (2022)

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors
por: Davis, Elizabeth J, et al.
Publicado: (2022)

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas
por: Coveler, Andrew L, et al.
Publicado: (2023)

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors
por: Naing, Aung, et al.
Publicado: (2020)

Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors
por: Conlon, Kevin, et al.
Publicado: (2021)

Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
por: Guigay, Joël, et al.
Publicado: (2021)

Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors
por: Tolcher, Anthony W, et al.
Publicado: (2023)

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
por: Postel-Vinay, Sophie, et al.
Publicado: (2023)

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
por: Gomez-Roca, Carlos, et al.
Publicado: (2022)

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
por: Frentzas, Sophia, et al.
Publicado: (2023)

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
por: Apolo, Andrea B, et al.
Publicado: (2020)

Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study
por: Verschraegen, Claire F, et al.
Publicado: (2020)

TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity
por: Kaminski, Michael F, et al.
Publicado: (2022)

CX-072 (pacmilimab), a Probody(®) PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
por: Naing, Aung, et al.
Publicado: (2021)

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
por: Aggarwal, Charu, et al.
Publicado: (2022)

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma
por: Strauss, Julius, et al.
Publicado: (2023)

Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment
por: Lin, Weiwei, et al.
Publicado: (2023)

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
por: Sanborn, Rachel E, et al.
Publicado: (2021)

Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors
por: Tapia, Coya, et al.
Publicado: (2020)

Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids
por: Meng, Qingda, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gal1304jhpit6qle8col75m91q